AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Study ID: STU 122014-025

Summary

Participant Eligibility

Cancer Related

Yes

Healthy Volunteers

No

UT Southwestern Principal Investigator

Patrick J Leavey

CHILDRENS ONCOLOGY GROUP OPERATIONS CTR

Bones and Joints

d904d1aa-466c-47da-aec2-fc0eb600741b